HeiLongJiang ZBD Pharmaceutical Co., Ltd. (603567.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 5.31

From 52W high−56.92%

Volume18.92M

Market capCNY 5.00B

P/E (TTM)−3.7x

P/S (TTM)9.8x

Div yield—

Key dataSep 18, 2026

Open

CNY 5.31

From 52W high

−56.92%

Volume

18.92M

Market cap

CNY 5.00B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.0x

P/E (TTM)

−3.7x

RSI (14)

41.4

MomentumView details →

1D Return

−5.67%

YTD Return

−40.65%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−3.7x

EV/EBITDA

−5.0x

EV/Sales

13.7x

P/S (TTM)

9.8x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

−72.94%

Net Margin

−317.72%

EBITDA Margin

−275.48%

ROE (TTM)

−26.58%

ROA (TTM)

−15.44%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

−75.19%

EPS YoY

—

FCF YoY

+386.35%

Revenue CAGR 3Y

−42.60%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−5.67%

YTD Return

−40.65%

1Y Return

−54.35%

RSI (14)

41.4

vs 50D SMA

−10.63%

vs 200D SMA

−26.67%

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

1.38x

Quick Ratio

1.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

−25.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

510.45M

Net Income (TTM)

−1.62B

Op. CF (TTM)

652.58M

Latest newsMore news →

Zhenbaodao's independent directors issued opinions on the Shanghai Stock Exchange's 2025 annual report inquiry letter, disclosing that the controlling shareholder had non-operationally occupied company funds of 233 million yuan (already disclosed) and an additional 66.0236 million yuan in 2022 through Heilongjiang Jinjiu Pharmaceutical Co., Ltd., all of which have been fully repaid.23d ago

Zhenbaodao announced its first-half 2026 results, reporting a net loss of 271 million yuan, compared with a loss of 78.29 million yuan in the same period of 2025.23d ago

Similar companies

吉贝尔688566.SH 千金药业600479.SH 圣诺生物688117.SH 人民同泰600829.SH Shenzhen Hepalink Pharmaceutical Group Co., Ltd.09989.HK 联环药业600513.SH Find similar companies →

Latest newsMore news →

Zhenbaodao's independent directors issued opinions on the Shanghai Stock Exchange's 2025 annual report inquiry letter, disclosing that the controlling shareholder had non-operationally occupied company funds of 233 million yuan (already disclosed) and an additional 66.0236 million yuan in 2022 through Heilongjiang Jinjiu Pharmaceutical Co., Ltd., all of which have been fully repaid.23d ago Zhenbaodao announced its first-half 2026 results, reporting a net loss of 271 million yuan, compared with a loss of 78.29 million yuan in the same period of 2025.23d ago Zhenbaodao received a letter of inquiry from the Shanghai Stock Exchange regarding its annual report and has responded, with multiple issues still under investigation.74d ago